Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Shares Issued (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Shares Issued for 12 consecutive years, with -$8.6 million as the latest value for Q2 2025.

  • Quarterly Shares Issued fell 106.38% to -$8.6 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was -$59.9 million through Sep 2025, down 109.47% year-over-year, with the annual reading at $337.6 million for FY2024, 29.74% up from the prior year.
  • Shares Issued for Q2 2025 was -$8.6 million at Madrigal Pharmaceuticals, down from $8.6 million in the prior quarter.
  • The five-year high for Shares Issued was $262.1 million in Q1 2024, with the low at -$66.1 million in Q2 2021.
  • Average Shares Issued over 5 years is $61.0 million, with a median of $6.2 million recorded in 2023.
  • The sharpest move saw Shares Issued surged 46759.08% in 2022, then tumbled 125.43% in 2024.
  • Over 5 years, Shares Issued stood at $545000.0 in 2021, then soared by 46759.08% to $255.4 million in 2022, then dropped by 7.71% to $235.7 million in 2023, then crashed by 125.43% to -$59.9 million in 2024, then surged by 85.58% to -$8.6 million in 2025.
  • According to Business Quant data, Shares Issued over the past three periods came in at -$8.6 million, $8.6 million, and -$59.9 million for Q2 2025, Q1 2025, and Q4 2024 respectively.